During the quarter, sales rose to SEK 120.2 million, an increase of 6% from SEK 113.3 million in the previous year. Growth for next year negatively impacted by launch delays, but long-term outlook ...
EQL Pharma is recruiting a new CSCO with a clear CMO/CDMO background. This means that the current Chief Supply Chain Officer (CSCO) Magnus Erreth will leave his position. Magnus has been active in ...
EQL Pharma AB (publ) will publish its year-end report for the fourth quarter, 2025/26, on Friday, May 8[th].
EQL Pharma CEO Axel Schörling has recently sold shares for approximately SEK 1.2 million to finance capital gains tax that arose upon redemption of the option program in September 2025.
EQL's key product Mellozzan® has now received Marketing Authorization approval from the health authority in Italy (AIFA), where it will be provided to patients by EQL's licensing partner Italfarmac...
